Management of Castration-Resistant, Taxane-Resistant Prostate Cancer

    Research output: Contribution to journalArticle

    2 Citations (Scopus)

    Abstract

    Metastatic castration-resistant prostate cancer that is progressing despite docetaxel chemotherapy is difficult to treat and often aggressive. If not previously used, modern androgen signaling inhibitors have established clinical activity in this setting. Cabazitaxel and radium-223 have also been shown to extend survival in appropriately selected patients. Carboplatin-containing chemotherapy regimens have not been studied in randomized trials with a survival endpoint, but they have demonstrated activity in phase II trials and are occasionally considered in the post-docetaxel setting. Recent identification of potentially exploitable targets in the molecular makeup of advanced prostate cancer has created opportunities for clinical trials of novel targeted agents, with poly(ADP-ribose) polymerase inhibitors yielding compelling early results in molecularly selected patients. Much remains to be done to improve the lot of patients with docetaxel-unresponsive metastatic castration-resistant prostate cancer.

    Original languageEnglish (US)
    Pages (from-to)633-636
    Number of pages4
    JournalOncology (Williston Park, N.Y.)
    Volume31
    Issue number8
    StatePublished - Aug 15 2017

    Fingerprint

    docetaxel
    Castration
    Prostatic Neoplasms
    Drug Therapy
    Radium
    Survival
    Carboplatin
    Androgens
    Clinical Trials
    taxane

    ASJC Scopus subject areas

    • Oncology
    • Cancer Research

    Cite this

    Management of Castration-Resistant, Taxane-Resistant Prostate Cancer. / Beer, Tomasz (Tom).

    In: Oncology (Williston Park, N.Y.), Vol. 31, No. 8, 15.08.2017, p. 633-636.

    Research output: Contribution to journalArticle

    @article{94d4847a519a487fa64ffcfa536c0542,
    title = "Management of Castration-Resistant, Taxane-Resistant Prostate Cancer",
    abstract = "Metastatic castration-resistant prostate cancer that is progressing despite docetaxel chemotherapy is difficult to treat and often aggressive. If not previously used, modern androgen signaling inhibitors have established clinical activity in this setting. Cabazitaxel and radium-223 have also been shown to extend survival in appropriately selected patients. Carboplatin-containing chemotherapy regimens have not been studied in randomized trials with a survival endpoint, but they have demonstrated activity in phase II trials and are occasionally considered in the post-docetaxel setting. Recent identification of potentially exploitable targets in the molecular makeup of advanced prostate cancer has created opportunities for clinical trials of novel targeted agents, with poly(ADP-ribose) polymerase inhibitors yielding compelling early results in molecularly selected patients. Much remains to be done to improve the lot of patients with docetaxel-unresponsive metastatic castration-resistant prostate cancer.",
    author = "Beer, {Tomasz (Tom)}",
    year = "2017",
    month = "8",
    day = "15",
    language = "English (US)",
    volume = "31",
    pages = "633--636",
    journal = "ONCOLOGY (United States)",
    issn = "0890-9091",
    publisher = "UBM Medica Healthcare Publications",
    number = "8",

    }

    TY - JOUR

    T1 - Management of Castration-Resistant, Taxane-Resistant Prostate Cancer

    AU - Beer, Tomasz (Tom)

    PY - 2017/8/15

    Y1 - 2017/8/15

    N2 - Metastatic castration-resistant prostate cancer that is progressing despite docetaxel chemotherapy is difficult to treat and often aggressive. If not previously used, modern androgen signaling inhibitors have established clinical activity in this setting. Cabazitaxel and radium-223 have also been shown to extend survival in appropriately selected patients. Carboplatin-containing chemotherapy regimens have not been studied in randomized trials with a survival endpoint, but they have demonstrated activity in phase II trials and are occasionally considered in the post-docetaxel setting. Recent identification of potentially exploitable targets in the molecular makeup of advanced prostate cancer has created opportunities for clinical trials of novel targeted agents, with poly(ADP-ribose) polymerase inhibitors yielding compelling early results in molecularly selected patients. Much remains to be done to improve the lot of patients with docetaxel-unresponsive metastatic castration-resistant prostate cancer.

    AB - Metastatic castration-resistant prostate cancer that is progressing despite docetaxel chemotherapy is difficult to treat and often aggressive. If not previously used, modern androgen signaling inhibitors have established clinical activity in this setting. Cabazitaxel and radium-223 have also been shown to extend survival in appropriately selected patients. Carboplatin-containing chemotherapy regimens have not been studied in randomized trials with a survival endpoint, but they have demonstrated activity in phase II trials and are occasionally considered in the post-docetaxel setting. Recent identification of potentially exploitable targets in the molecular makeup of advanced prostate cancer has created opportunities for clinical trials of novel targeted agents, with poly(ADP-ribose) polymerase inhibitors yielding compelling early results in molecularly selected patients. Much remains to be done to improve the lot of patients with docetaxel-unresponsive metastatic castration-resistant prostate cancer.

    UR - http://www.scopus.com/inward/record.url?scp=85050432577&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85050432577&partnerID=8YFLogxK

    M3 - Article

    VL - 31

    SP - 633

    EP - 636

    JO - ONCOLOGY (United States)

    JF - ONCOLOGY (United States)

    SN - 0890-9091

    IS - 8

    ER -